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Genome-wide association studies to identify loci respon-
sible for platelet function and cardiovascular disease sus-
ceptibility have repeatedly identified polymorphisms
linked to a gene encoding platelet endothelium aggrega-
tion receptor 1 (PEAR1), an “orphan” cell surface receptor
that is activated to stabilize platelet aggregates. To inves-
tigate how PEAR1 signaling is initiated, we sought to
identify its extracellular ligand by creating a protein mi-
croarray representing the secretome and receptor reper-
toire of the human platelet. Using an avid soluble recom-
binant PEAR1 protein and a systematic screening assay
designed to detect extracellular interactions, we identi-
fied the high affinity immunoglobulin E (IgE) receptor sub-
unit  (FcR1) as a PEAR1 ligand. FcR1 and PEAR1
directly interacted through their membrane-proximal Ig-
like and 13th epidermal growth factor domains with a
relatively strong affinity (KD  30 nM). Precomplexing
FcR1 with IgE potently inhibited the FcR1-PEAR1 in-
teraction, and this was relieved by the anti-IgE therapeutic
omalizumab. Oligomerized FcR1 potentiated platelet ag-
gregation and led to PEAR1 phosphorylation, an effect that
was also inhibited by IgE. These findings demonstrate how
a protein microarray resource can be used to gain impor-
tant insight into the function of platelet receptors and
provide a mechanistic basis for the initiation of PEAR1 sig-
naling in platelet aggregation. Molecular & Cellular Pro-
teomics 14: 10.1074/mcp.M114.046946, 1265–1274, 2015.
Platelets play a vital role in preserving blood circulation in
response to vessel injury by detecting lesions, aggregating to
form a hemostatic plug, and nucleating the formation of a
fibrin-rich, injury-occluding clot. Although necessary to pre-
vent blood loss at sites of tissue trauma, clot formation must
also be attenuated to prevent blockage of the vasculature
serving vital organs that would cause life-threatening ische-
mia and infarction. Inappropriate platelet aggregation and
vessel occlusion, often triggered by atherosclerotic plaque
rupture, is a major pathological process that is a major con-
tributor to cardiovascular disease, which is the leading cause
of mortality worldwide (1). With the eventual aim of guiding the
development of new treatments and diagnostic assays,
genome-wide association studies using large patient cohorts
have identified several genetic loci that are associated with
cardiovascular disease susceptibility and platelet function (2,
3). Among the candidate genes identified, polymorphisms
linked to PEAR1 have been repeatedly linked to natural vari-
ation in response to platelet agonists in several independent
studies (3–7). PEAR1 encodes platelet endothelium activation
receptor 1 (PEAR1;1 also known as multiple epidermal growth
factor-like domain protein 12 (MEGF12) or JEDI-1), a platelet
cell surface receptor that was originally identified as a protein
phosphorylated in response to platelet aggregation (8, 9).
PEAR1 is expressed at low levels on the surface of circulating
platelets but is significantly up-regulated during platelet acti-
vation when released from cytoplasmic -granules (8). Con-
sistent with polymorphisms linked to PEAR1 being associated
with cardiovascular disease and platelet function, PEAR1-
mediated signaling was shown to reinforce and stabilize the
interactions between platelets within a forming aggregate (8).
PEAR1 is an orphan receptor, and an important unanswered
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question in understanding the mechanism of PEAR1 function
during platelet aggregation, therefore, is the identification of
its activating ligand.
Identifying interactions between membrane-embedded re-
ceptor proteins is technically challenging, and many com-
monly used approaches such as biochemical purifications are
generally not suitable to detect them. This is largely due to the
amphipathic nature of membrane-embedded proteins that
makes them difficult to solubilize in detergents that retain their
native conformation and the fact that their extracellular inter-
actions are often highly transient, having half-lives of just
fractions of a second (10). To address these issues, we and
others have developed assays based on detecting direct pro-
tein interactions between the entire ectodomains of cell sur-
face receptors expressed as soluble recombinant proteins in
eukaryotic cells (11–14). Using this approach, binding avidity
can be increased by the purposeful inclusion of oligomerizing
tags to overcome the fleeting nature of these interactions. In
our assay, avidity-based extracellular interaction screen
(AVEXIS), arrays of monomeric biotinylated “bait” proteins are
screened against multimerized, enzyme-tagged, highly avid
“preys” (11, 15); a schematic of the assay is shown in sup-
plemental Fig. S1. The likelihood that the extracellular binding
functions of receptors are preserved is increased by express-
ing whole ectodomains in mammalian cells so that structurally
critical posttranslational modifications such as disulfide
bonds are faithfully added. Consequently, this method has
identified interactions that have subsequently been demon-
strated to be essential for cellular recognition processes in
vivo (16–18).
In this study, we have compiled a protein resource repre-
senting the cell surface receptor repertoire and secretome of
the human platelet that will be useful to identify intercellular
interactions important for platelet biology. As an example, we
identify the activating ligand for PEAR1 as the high affinity
immunoglobulin E (IgE) receptor subunit  (FcR1) and show
that multimerized FcR1 potentiated platelet aggregation
and led to PEAR1 phosphorylation, an effect that was specif-
ically inhibited by IgE.
EXPERIMENTAL PROCEDURES
Human Platelet Protein Selection and Expression Plasmid Con-
struction—After compiling a list of platelet receptor proteins and
classifying them into structural categories, the extent of each ectodo-
main was identified by careful manual examination of its structural
features such as signal peptides, transmembrane regions, and gly-
cosylphosphatidylinositol anchors; for secreted proteins, the entire
protein was used. The ectodomain regions were codon-optimized for
human expression, chemically synthesized with unique flanking NotI
(5) and AscI (3) restriction sites (GeneArt AG), and subcloned into
bait expression plasmids according to its structural class. Although
we have previously expressed type I/glycosylphosphatidylinositol-
anchored and secreted proteins for interaction screening (11), we
designed new expression vectors to express the ectodomains of type
II and multispan transmembrane proteins in a way that would most
appropriately preserve their structure when presented at the cell
surface in vivo. Similarly, for multimeric protein complexes such as
integrins, glycoprotein 1b, and fibrinogen, care was taken to design
constructs that would promote correct and active complex formation.
The truncated fragments of PEAR1 and FcR1 were designed based
on their domain structures, amplified by PCR from the full-length
constructs, and cloned into an expression vector containing an ex-
ogenous signal peptide and C-terminal His6 and biotinylatable pep-
tide sequence. The 218- and 325-amino acid fragments encoding the
C3–4 and C2–4 domains of the IgE constant heavy chain were
amplified from plasmid pFUSE-CHIg-hE (Invivogen) and cloned into a
vector containing an exogenous signal peptide and C-terminal His6
tag. IgE fragments were expressed and purified as described below.
All plasmid constructs are openly available from Addgene.
Recombinant Protein Expression—All proteins were produced by
transient transfection using human embryonic kidney HEK293E cells
as described (11) to ensure posttranslational modifications such as
disulfide bonds and glycans were added. Proteins were purified using
their His6 tag using a bespoke supernatant loading rig and 96-well
Ni2-nitrilotriacetic acid filter plates (15). Heat-labile immunoreactivity
to demonstrate folding was confirmed by heat-denaturing the pro-
teins for 10 min at 90 °C before capture on a streptavidin-coated plate
via their biotin tag and determination of immunoreactivity by ELISA as
described (19).
Construction of the Human Platelet Receptor Protein Microarray—
Normalized bait proteins were diluted in phosphate-buffered saline
(PBS) supplemented with 50% glycerol, 0.02% Tween, and 0.5%
bovine serum albumin (BSA) prior to printing. Bait proteins were
printed on streptavidin-coated slides that also contained an inert
hydrogel coating (XanTec) using a Marathon arrayer (Arrayjet) at 60%
relative humidity according to the manufacturer’s instructions. Printed
slides were incubated for 1 h at 60% relative humidity and blocked
with PBS containing 1% BSA and 10 mM D-biotin for 45 min. Slides
were then incubated with normalized prey proteins for 1 h before
being incubated with an anti-FLAG-horseradish peroxidase antibody
(Sigma; 1:1000) for 1 h and finally detected by tyramide signal am-
plification Alexa Fluor 555 substrate (Invitrogen) for 1 h. Between
different incubation steps, slides were washed three times in PBS
buffer containing 0.1% Tween 20 with gentle rocking. Arraying, incu-
bations, and washing steps were performed at 22 °C. Positive inter-
actions were identified and quantified by scanning slides with a
ScanArray Express microarray scanner (PerkinElmer Life Sciences) at
550 nm.
AVEXIS Interaction Screening—To determine the effect of IgE/
omalizumab and map the interacting domains of the FcR1-PEAR1
interaction, we used the AVEXIS method formatted on streptavidin-
coated 96-well microtiter plates as described (11, 17). Briefly, bait and
prey proteins were first normalized to activities suitable for the
AVEXIS assay (20). Biotinylated baits that had been either purified or
dialyzed against HEPES-buffered saline were immobilized in strepta-
vidin-coated 96-well microtiter plates (Nunc). Preys were incubated
for 2 h and washed three times with PBS and 0.1% Tween 20 and
once in PBS, 125 g/ml nitrocefin was added, and absorbance values
were measured at 485 nm on a Pherastar Plus (BMG Laboratories). A
protein consisting of the Cd4d34 tag alone was used as a negative
control bait, and a biotinylated anti-Cd4 monoclonal antibody (anti-
prey) was used as a positive control as required.
Surface Plasmon Resonance Studies—All surface plasmon reso-
nance studies were performed on a Biacore T100 instrument essen-
tially as described (17). Purified analyte proteins were resolved by gel
filtration just prior to use in surface plasmon resonance experiments.
Increasing concentrations of proteins were injected at 10 l/min for
equilibrium analysis or high flow rates (100 l/min) for kinetic studies
to minimize the confounding effects of analyte rebinding. Both kinetic
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and equilibrium binding data were analyzed using the manufacturer’s
Biacore T100 evaluation software (Biacore).
Platelet Aggregometry Assays—Venous blood was collected from
normal donors following guidelines from the ethics committee of the
Leuven University Hospital (number B322201111373/S53239). Plate-
let-rich plasma was prepared, and platelet aggregation was moni-
tored as described (8). Platelets (4  105/l) were preincubated with
either soluble recombinant purified pentameric proteins extensively
dialyzed into PBS (PEAR1 (s5-PEAR1), FcR1 (s5-FcR1), and
control rat Cd200 all used at 10 g/ml) or the commercially available
antibodies human IgE (10 g/ml (53 nM); Abcam), anti-PEAR1 (3
g/ml; R&D Systems), and omalizumab (10 g/ml (67 nM); Xolair®,
Novartis) at 37 °C as appropriate. The IgE fragments were used at an
equimolar concentration of 67 nM. Platelet aggregation was triggered
by collagen with the concentration adjusted to reach 40–70% platelet
aggregation for each donor and measured as the percentage of
change in light transmission relative to a blank (buffer without plate-
lets) set to 100%.
Western Blotting—Western blotting was performed essentially as
described (8) using the primary antibodies PEAR1-EC antibody (R&D
Systems), PEAR1-EC antibody (Santa Cruz Biotechnology), FcR1
antibody (LifeSpan Biosciences), anti-PLC2 (Sigma), anti-PLC2-P
(Cell Signaling Technology), anti-AKT-P (Cell Signaling Technology),
and anti-phosphoprotein (Tyr(P)) 4G10 Platinum (Millipore). After add-
ing horseradish peroxidase-conjugated secondary antibodies (Dako),
immunoreactive bands were visualized by ECL (Amersham Biosci-
ences). PEAR1 phosphorylation on Tyr residues, referred to as
PEAR1-P, was evaluated after immunoprecipitation with PEAR1-EC
antibody and detection of Tyr(P) by 4G10 platinum as previously
described (8).
Platelet Immunocytochemistry—Platelets were stained essentially
as described (8) using the primary antibodies anti-human IgE (5
g/ml; BD Pharmingen), anti-human FcRI (5 g/ml; eBioscience),
and anti-human PEAR1 (2 g/ml; R&D Systems); washed; and de-
tected using an appropriate Alexa Fluor 488-conjugated secondary
antibody (1:200; Invitrogen) for 60 min at 37 °C. Coverslips were
mounted with 4,6-diamidino-2-phenylindole ProLong Gold (Invitro-
gen), sealed on glass slides, and analyzed using a Zeiss ELYRA
superresolution microscope and Zen 2011 image software (Carl
Zeiss).
RESULTS
A Protein Resource Representing the Secretome and Re-
ceptor Repertoire of the Human Platelet—To identify an acti-
vating ligand for PEAR1, we first created a protein library that
represented the cell surface receptor repertoire and secre-
tome of the human platelet expressed as secreted recombi-
nant proteins. We and others have previously only expressed
type I/glycosylphosphatidylinositol-anchored and secreted
proteins for large scale extracellular interaction screening (11–
14), but because platelets also express cell surface proteins
from other structural classes, we designed new expression
plasmids. We constructed these new expression plasmids
with the goal of preserving the structure of the receptor when
displayed at the platelet surface (Fig. 1A). In the case of
multimeric protein complexes such as integrins, glycoprotein
1b, and fibrinogen, care was taken to design the constructs
such that they would promote correct and active complex
formation; for example, secretion of integrin  chains can be
dependent on the presence of the  chain (21), and so tags
were only added to the  chain, ensuring the expression of a
tagged / complex in an active conformation (22) (Fig. 1A).
We next compiled a list of secreted and membrane proteins
expressed by human platelets from 18 proteomic data sets
and the literature (supplemental Table S1). To increase the
chances of identifying functionally relevant interactions, each
protein was classified into one of six structural categories. The
entire extent of the ectodomain region was then determined,
and an expression construct was manually designed by pair-
ing it with an appropriate expression vector. The final library
contained 173 proteins and complexes (76 type I, seven gly-
cosylphosphatidylinositol-anchored, 14 type II, 57 secreted,
seven heterodimeric complexes, and 12 multispan transmem-
brane proteins) represented by a total of 178 plasmids (sup-
plemental Table S2). The proteins were expressed and puri-
fied as monomeric biotinylated “baits” in mammalian cells so
that structurally important posttranslational modifications
such as disulfide bonds and glycans were added. Similar to
other secreted recombinant protein libraries that we (11, 17,
23, 24) and others (13, 25, 26) have made, expression levels
varied widely but averaged 3 g/ml (supplemental Table
S2). After purification, 126 proteins were expressed at suffi-
cient levels for our interaction screens. As expected, Western
blots of the protein library showed that the vast majority (113
of 121; 93%) of proteins exhibited mass heterogeneity cen-
tered on their expected size, suggesting the presence of
different glycoforms (Fig. 1B). The recombinant proteins were
antigenically active as assessed by demonstrating heat-labile
immunoreactivity to a panel of monoclonal antibodies recog-
nizing at least one protein from each structural category (sup-
plemental Fig. S2A). The library of biotinylated bait proteins
was serially diluted and arrayed on streptavidin-coated glass
slides (supplemental Fig. S3). Proteins immobilized on the
slides retained their immunoreactivity to monoclonal antibod-
ies known to stain native proteins at the cell surface (supple-
mental Fig. S2B). These plasmids and recombinant protein
library represent a valuable resource for the investigation of
human platelet biology particularly in regard to the role of
these proteins in thrombosis.
Systematic Interaction Screening of the Platelet Receptor
Microarray Identified FcR1 as a Ligand for PEAR1—To
identify an activating ligand for PEAR1 during platelet aggre-
gation, we systematically screened the human platelet recep-
tor microarray using the AVEXIS assay, which required ex-
pressing the entire ectodomain of PEAR1 as a recombinant
pentameric, FLAG-tagged soluble “prey.” Probing the array
with a control pentameric FLAG-tagged prey protein labeled
the high affinity IgG receptor Fc2 (which directly bound the
anti-FLAG antibody) and P4HB, a bait that presumably inter-
acted with the tags on the control prey (Fig. 2A). Screening the
receptor microarray with the PEAR1 prey identified the high
affinity IgE-binding subunit FcR1 as a PEAR1 ligand (Fig.
2B and supplemental Fig. S4). Because PEAR1 was pre-
sented as a bait on the microarray, to rule out any possible
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artifacts, we expressed the entire ectodomain of FcR1 as a
prey protein and rescreened the array. As expected, we ob-
served that the FcR1 prey interacted with the PEAR1 bait,
showing that we could detect the same interaction but in the
reciprocal bait-prey orientation (Fig. 2C).
PEAR1 and FcR1 Directly Interact through Their Mem-
brane-proximal Domains—To validate and quantify the inter-
action, we used surface plasmon resonance and observed
clear saturable binding between PEAR1 and FcR1 with an
equilibrium binding constant (KD) of 27.4  1.3 nM (Fig. 3A).
The saturable binding behavior demonstrated the specificity
of the interaction, which had a remarkably high affinity when
compared with similar receptor-ligand interactions, which are
usually in the micromolar range when measured using the
same approach (10). An independent kinetic analysis con-
firmed this and revealed that the higher affinity was largely
FIG. 1. Design and expression of a human platelet receptor library for common structural classes of cell surface and secreted
proteins for AVEXIS. A, schematics show the design of ectodomain expression constructs. Type II and multispan proteins contained an
exogenous signal peptide (Exg.SP), whereas the others retain their endogenous signal peptide (End.SP). Heteromeric complexes such as the
integrins shown here were tagged on only one chain to ensure expression of only tagged complexes. *, stop codon. B, an anti-biotin Western
blot of the 121 bait proteins organized into their structural categories. The majority of proteins were expressed at the expected size with little
processing. Numbering is according to supplemental Table S2; note that the five expressed heteromeric complexes are not included because
only one chain would have been detected. GPI, glycosylphosphatidylinositol; Bio, biotin; 6H, His6; ITG, integrin; TM, transmembrane.
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due to a comparatively slow dissociation rate constant (Fig.
3B). By using the AVEXIS assay and a series of structure-
guided truncations in both PEAR1 and FcR1, we showed
that the minimal FcR1 binding unit on PEAR1 was con-
tained solely within the 45 amino acids comprising the 13th
epidermal growth factor domain (Fig. 4, A and C). Similarly,
the PEAR1 binding site was located within the membrane-
proximal Ig-like domain of the FcR1 ectodomain, the same
domain bound by IgE (27) (Fig. 4, B and C), raising the pos-
sibility that IgE may prevent PEAR1 binding when complexed
with its receptor. Indeed, IgE, when bound to FcR1, could
potently inhibit the FcR1-PEAR1 interaction at low concen-
trations, consistent with the high affinity of IgE for FcR1
(Fig. 4D). To show that this inhibitory effect was due to block-
ing of the FcR1-PEAR1 interaction and not steric interfer-
ence with the large (190-kDa) IgE molecule, we demonstrated
that smaller subfragments of the IgE heavy chain that bound
FcR1 also blocked the FcR1-PEAR1 interaction (Fig. 4E).
To demonstrate the specificity of this effect, we showed that
addition of an anti-IgE monoclonal antibody that prevents IgE
binding to FcR1 (omalizumab) could relieve the inhibitory
effect of IgE on the FcR1-PEAR1 interaction (Fig. 4F).
Oligomerized FcR1 Specifically Potentiates Platelet Ag-
gregation and Phosphorylates PEAR1—To investigate the role
of the FcR1-PEAR1 interaction in platelet activation, we
confirmed cell surface expression of PEAR1 (8, 9) and FcR1
(28, 29) by platelets using both Western blotting and immu-
nocytochemistry (supplemental Fig. S5). Unlike PEAR1 (8), we
did not observe any increase in the cell surface expression of
FcR1 after platelet activation. We next added clustered
soluble oligomers (pentamers) of PEAR1 and FcR1 to plate-
let aggregation assays and showed that they did not by
themselves trigger platelet aggregation (data not shown). Pre-
incubating unactivated platelets with FcR1 oligomers fol-
lowed by collagen stimulation, however, potentiated platelet
aggregation (Fig. 5A). The specificity of this effect was dem-
onstrated by precomplexing the FcR1 pentamers with IgE
to completely block FcR1-mediated PEAR1 signaling, sug-
gesting the possibility that IgE could act as an endogenous
plasma-borne restrictive regulator of thrombus formation (Fig.
FIG. 2. A human platelet secretome and receptor protein mi-
croarray identifies FcR1 as a ligand for PEAR1. Soluble recom-
binant biotinylated proteins representing the secretome and receptor
repertoire of the human platelet were purified and arrayed in six 3-fold
dilutions on streptavidin-coated slides. A, the array was screened
with a control (rat Cd200) pentamerized FLAG-tagged prey that
bound the background baits FcR2 (red box) and P4HB (white box).
B, PEAR1 prey additionally interacted with the FcR1 bait (orange
box) when compared with the control in A; fluorescence intensities
are quantified in supplemental Fig. S4. C, FcR1 prey additionally
interacted with the PEAR1 bait (blue box) in comparison with the
control. Note that the nine regularly spaced markers are orientation
markers and that the boxed areas marked on the array enclose the
location of the six spots containing the dilutions of the named immo-
bilized baits (see supplemental Fig. S3).
FIG. 3. FcR1 and PEAR1 directly and specifically interact with a relatively high affinity. A, purified monomeric FcR1-Cd4-His6 was
serially diluted and injected over immobilized PEAR1 until equilibrium was achieved (inset). Binding data that had been reference-subtracted
were plotted as a binding curve, and a KD of 27.4  1.3 nM was calculated. B, association and dissociation rate constants derived from an
independent kinetic analysis of the FcR1-PEAR1 interaction were consistent with the equilibrium analysis. Seven serial dilutions of purified,
soluble FcR1-Cd4-His6 were injected over immobilized PEAR1 (black lines), and kinetic parameters for the interaction derived from a 1:1
binding model were fitted to the family of sensorgrams (red lines). 6H, His6; RU, response units.
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FIG. 4. The FcR1-PEAR1 interaction is mediated by membrane-proximal domains and can be specifically inhibited by IgE. A, a
schematic illustrating the domain organization of the PEAR1 receptor in the membrane. Expressed fragments of the PEAR1 protein are
represented by orange bars, and the ticks and crosses indicate the ability of the fragments to bind the full-length (FL) ectodomain of FcR1
as determined by AVEXIS; a similar summary for FcR1 but tested for binding to PEAR1 is shown in B. C, binding data using AVEXIS showing
that the 13th epidermal growth factor (EGF) domain of PEAR1 and the second Ig-like domain of FcR1 are necessary and sufficient for
binding. Bars represent means  S.E. (n  3). D, the FcR1-PEAR1 interaction detected by AVEXIS using PEAR1 as a plate-immobilized bait
was completely inhibited by low (IC50  0.5 ng/ml) concentrations of IgE (filled circles) but not control IgG (open circles). A control interaction,
rat Cd200-Cd200 receptor (Cd200R) (squares), was not inhibited by either antibody. E, the indicated concentrations of purified full-length (FL)
and both smaller fragments of the IgE constant heavy chain (C2–4) and (C2–3) were preincubated with the FcR1 prey before being added
to the PEAR1 bait, and the interaction was detected using AVEXIS. Data points are mean  S.E. (n  3). F, the FcR1-PEAR1 interaction was
detected using AVEXIS, and the inhibition by IgE (IgE alone; filled circles) could be relieved by the addition of 2.5 g of omalizumab (open
circles). Data points are mean  S.E. (n  3). Error bars represent S.E. EMI, EMILIN-family domain.
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5B). PEAR1 oligomers modestly inhibited platelet aggregation
(Fig. 5A) and did not trigger known FcR1 signaling effectors
such as the phosphorylation of PLC (data not shown), sug-
gesting that they competed with membrane-tethered PEAR1
for FcR1 binding. Finally, oligomerized FcR1, but not a
control, was able to trigger PEAR1 phosphorylation with sim-
ilar potency to an activating anti-PEAR1 antibody (Fig. 5C)
and led to clear AKT phosphorylation, a known mediator of
PEAR1 signaling (8) (Fig. 5D).
DISCUSSION
Platelets perform a delicately balanced role in hemostasis
because they must detect and seal vascular breaches to
restrict bleeding while ensuring a proportionate response to
avoid vascular occlusion and maintain circulation. Interac-
tions between receptor proteins displayed on the surface of
platelets are a major class of thrombogenic regulator, and
we report here a large recombinant protein library repre-
senting the secretome and receptor repertoire of the human
platelet in a format suitable for systematic extracellular in-
teraction screening using the AVEXIS assay. Importantly,
we have expanded the utility of this assay to include recep-
tor proteins from a greater range of structural classes as we
work toward achieving a cell type- rather than a protein
family-orientated screening approach; only the latter has
been possible in the past (11–14, 24). Central to this ap-
proach is the use of a mammalian expression system to
promote the correct folding of the receptor ectodomains,
which we have previously shown can identify interactions
that are functionally relevant in vivo (16–18). The human
platelet protein library will be a useful resource in further
defining the role of platelet receptors and their interactions
in cardiovascular disease, particularly because all the ex-
pression plasmids have been made openly available
through the Addgene repository (30).
We have demonstrated the usefulness of this resource by
identifying the ligand for PEAR1, an “orphan” platelet receptor
that is of topical interest because it has been identified in
several recent independent genome-wide association studies
linking it with variation in patients’ responses to thrombogenic
agonists in both health and disease (3–7). Because both
FcR1 and PEAR1 are expressed on the same cell, this
raises the possibility that the two proteins might interact either
in “cis” within the same membrane or in “trans” between
neighboring cells. Although these need not be mutually ex-
FIG. 5. Oligomerized FcR1 promotes platelet aggregation and phosphorylates PEAR1. A, soluble recombinant pentamerized (s5)
PEAR1 ectodomains modestly inhibited whereas a similar s5-FcR1 protein strongly promoted platelet aggregation relative to a control (rat
s5-Cd200) when added prior to collagen-induced platelet aggregation. B, precomplexing s5-FcR1 with IgE completely inhibited s5-FcR1-
potentiated aggregation of collagen-activated platelets. C, oligomeric FcR1, but not a control protein, triggered the phosphorylation of
PEAR1 (top panel) in human platelets with similar potency to an anti-PEAR1 antibody (Ab) (lower panel); total PEAR1 protein was detected as
a loading control. D, oligomeric FcR1 induced tyrosine phosphorylation in human platelets as shown by anti-phosphotyrosine (P-Tyr)
Western blotting of lysates. Phosphorylation of PEAR1 and AKT but not PLC2 (a mediator of FcR1 signaling) was observed. Total PLC2
protein was used as a loading control. Aggregation data are representative from at least 10 independent experiments.
FcR1 Is a PEAR1 Ligand
Molecular & Cellular Proteomics 14.5 1271
clusive, PEAR1 phosphorylation is known to be dependent
upon platelet contact (8, 9) within forming aggregates, sug-
gesting that the interaction is likely to occur in trans. The
kinetic analysis of the interaction between the soluble mono-
meric proteins suggest that the two proteins interact with a
1:1 stoichiometry, although both proteins are likely to form
signaling-competent clusters within the membrane, consis-
tent with previous findings that bivalent, but not monovalent,
anti-PEAR1 antibodies trigger PEAR1 phosphorylation (8).
Soluble oligomers of FcR1, but not PEAR1, triggered
known signaling effectors, consistent with a unidirectional
signal triggered by the FcR1 ligand through the PEAR1
receptor.
The function of the high affinity IgE receptor on platelets is
poorly characterized, but previous work is consistent with the
established role of IgE in immunity to parasitic infections
because cross-linking FcR1 on the platelet surface trig-
gered platelet cytotoxicity to a parasitic worm, Schistosoma
mansoni (29). Why FcR1 has been adopted in the regulation
of platelet biology is currently unclear, but perhaps the
ability to block the interaction with endogenous plasma-
borne IgE provides a clue. In healthy individuals, the con-
centration of circulating IgE is very low at 0.5 nM (31).
Because the affinity of FcR1 for IgE is within the same
range (KD in the sub-nM range (32) and about 2 orders of
magnitude higher than the affinity for PEAR1), this would
suggest that in normal circulation a significant fraction, but
not all (as shown in Hasegawa et al. (28)), of any FcR1 on
the surface of resting platelets will be bound by IgE and
unable to interact with PEAR1. Where circulating levels of
IgE are increased, for example in atopic patients (31), this
would significantly decrease the amount of IgE-free FcR1
on the platelet surface available for PEAR1 binding. This is
consistent with reports of a systemic lack of secondary
platelet responsiveness in atopic patients, an observation
that in one study was correlated with elevated IgE levels
(33–36). Others, however, have not replicated these findings
(37, 38), suggesting a more complex relationship between
circulating IgE levels and platelet function.
The controlled reduction of circulating IgE can be achieved
in humans in the treatment of allergy with a humanized anti-
IgE monoclonal antibody (omalizumab) that is currently li-
censed for the treatment of severe persistent allergic asthma
(39). It is a systemic anti-IgE agent that prevents the interac-
tion of IgE with its receptors, reducing plasma IgE levels by
99% and down-regulating FcR1 on mast cells and basophils
(40, 41). We have shown here that omalizumab is able to
relieve the IgE-mediated inhibition of the FcR1-PEAR1 in-
teraction, suggesting that omalizumab treatment could lead
to alterations in the regulation of PEAR1 signaling. Indeed,
concerns have recently been raised about an increased risk of
arterial thrombotic events, particularly myocardial infarction
and stroke, linked to the use of omalizumab (Ref. 42 and
references therein). In conclusion, we believe that the platelet
receptor protein microarray and plasmid resource will be a
valuable tool in cardiovascular disease research, and the
identification of FcR1 as a ligand for PEAR1 makes an
important contribution toward understanding the mechanistic
role this receptor plays in platelet function and cardiovascular
disease.
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